Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P840064/S094

VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscosurgical System; DISCOVISC Ophthalmic Viscosurgical

Alcon Laboratories · Decision date Oct 1, 2026

MEDTECHLEDGER EXPLANATIONP840064/S094

What did the FDA decide?

FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-01 for PMA supplement P840064/S094 from Alcon Laboratories. The supplement covers a change in the Endotoxin testing program for the subject ophthalmic viscosurgical devices, including test article preparation and individual component testing. The listed products are VISCOAT Ophthalmic Viscosurgical Device, DUOVISC Ophthalmic Viscosurgical System and DISCOVISC Ophthalmic Viscosurgical, classified under product code LZP in the ophthalmic specialty.

The recorded reason is a process change involving a manufacturer, sterilizer, packager or supplier. This entry documents a testing-program change within the existing PMA rather than an approval of the whole device system, and the source does not specify which endotoxin test methods, acceptance limits or component-level preparations were accepted. No FDA documents were included, so the decision letter and any conditions of the OK30 action remain unavailable here.

Whether the revised endotoxin testing affects finished-device release specifications or only in-process controls is not stated in the source data, and no clinical or legal conclusions follow from this record.

FDA approval order statement

a change in the Endotoxin testing program for the subject ophthalmic viscosurgical devices (OVDs), including test article preparation and individual component testing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 1, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P840064/S094
Regulatory pathway
PMA supplement
Product code
LZP
Decision code
OK30
Decision date
Oct 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: AID, SURGICAL, VISCOELASTIC.

Product code
LZP
FDA device class
3

For the original device and its historical approval scope, see PMA P840064. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P840064 · Original PMA

    VISCOAT(TM)/DVOVISC/DISCOVISC OPHTHALMIC VISCOSURGICAL DEVICES

  2. P840064/S094 received

    Application receipt date recorded by FDA.

  3. P840064/S094 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P840064. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P840064

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon LaboratoriesPMA approvalApr 30, 1986FDA

Explore the linked device profile

Other records with product code LZP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Laboratories

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy., Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records